Market Place
Sourcing Support
Eli Lilly`s Jaypirca gets US nod for mantle cell lymphoma
28 Jan 2023 //
ENDPTS
Lilly’s Loxo rounds out the PhI/II data for lymphoma drug under FDA review
12 Dec 2022 //
ENDPTS
Lilly, Foghorn Collaborate for Novel Oncology Targets Using Gene Traffic Control
13 Dec 2021 //
PRNEWSWIRE
Loxo Oncology at Lilly Announces Details of Presentations at 2021 AACR-NCI-EORTC
07 Oct 2021 //
PRNEWSWIRE
Lilly and Kumquat Biosciences Discover and Develop Novel Small Molecules
29 Jul 2021 //
PRNEWSWIRE
Loxo Oncology at Lilly Announces Publication of Pirtobrutinib (LOXO-305)
05 Mar 2021 //
PRNEWSWIRE
Lilly cancer R&D chief Bilenker quits, handing reins to deputy
03 Feb 2021 //
FIERCE BIOTECH
Eli Lilly`s new cancer R&D chief has some things to say about drug discovery
02 Feb 2021 //
ENDPTS
Josh Bilenker ends his brief role in an unusual experiment at Eli Lilly, bowing
29 Jan 2021 //
ENDPTS
Lilly expands its cancer drug work with bet on dual-acting antibodies
20 Jan 2021 //
BIOPHARMADIVE
With new data and a storied history, Eli Lilly’s blood cancer pill is looking
07 Dec 2020 //
STATNEWS
Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN
07 Dec 2020 //
PRNEWSWIRE
Lilly to pit Loxo cancer drug against top-selling rival after strong results
07 Dec 2020 //
BIOPHARMADIVE
Loxo at Lilly Announces Updated Data from the Phase 1/2 BRUIN Trial for LOXO-305
07 Dec 2020 //
PRNEWSWIRE
Loxo & Eli Lilly show off PhI/II for their BTK inhibitor mantle cell lymphoma
05 Dec 2020 //
ENDPTS
Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical
05 Dec 2020 //
PRNEWSWIRE
Loxo Oncology at Lilly Announces Details of LOXO-305 Presentations at (ASH)
04 Nov 2020 //
PRNEWSWIRE
FDA approves Eli Lilly drug for thyroid, lung cancers driven by a genetic
08 May 2020 //
REUTERS
As pipeline fattens, Lilly commits $470M for new plant with 460 jobs
22 Jan 2020 //
FIERCE PHARMA
Alexion`s neuro bet, Rubius` trial troubles and biotech`s gene therapy
14 Jan 2020 //
BIO PHARMA DIVE
Lots of cash and tasty targets signal deals to come
08 Jan 2020 //
FIERCE PHARMA
Lots of cash and tasty targets signal deals to come
08 Jan 2020 //
FIERCE PHARMA
Lots of cash and tasty targets signal deals to come
07 Jan 2020 //
FIERCE PHARMA
Eli Lilly spotlights early oncology in first pipeline review since R&D shift
17 Dec 2019 //
ENDPTS
ASH: Eli Lilly plots `ambitious` cancer program after sharing early BTK data
09 Dec 2019 //
FIERCE BIOTECH
ESMO: Lilly`s RET drug shrinks half of rare thyroid cancers
30 Sep 2019 //
FIERCE BIOTECH
Lilly`s RET drug shrinks more than half of rare thyroid cancers
29 Sep 2019 //
FIERCE BIOTECH
Lilly`s RET drug, nabbed in Loxo buyout, hits 68% ORR in lung cancer
10 Sep 2019 //
FIERCEBIOTECH
Inside drugmakers` strategy to boost cancer medicines with `Lazarus effect`
06 Sep 2019 //
REUTERS
Drugmakers’ strategy to boost cancer medicines with “Lazarus effect
05 Sep 2019 //
CNBC
How one hot protein family is driving cancer drug deals: report
21 Aug 2019 //
FIERCE PHARMA
Roche cancer drug the 3rd approved for pan-tumor use
16 Aug 2019 //
BIOPHARMADIVE
Eli Lilly cancer chief replaced by Loxo CEO (for now)
08 Aug 2019 //
FIERCE BIOTECH
Array played with Pfizer’s eagerness to land a deal on time
01 Jul 2019 //
FIERCE PHARMA
Who`s the next Big Pharma takeout target? Biogen, uniQure, AZ top the list
26 Jun 2019 //
FIERCE PHARMA
England to fast-track tumour agnostic drugs like Vitrakvi if the price is right
22 Jun 2019 //
PM LIVE
Eli Casdin backs Codexis` platform tech with $50M equity buy
21 Jun 2019 //
ENDPTS
Roche fields first approval for Rozlytrek
19 Jun 2019 //
ENDPTS
Pfizer, ‘never say never’ with big M&A, inks $11.4B Array cancer deal
18 Jun 2019 //
FIERCE PHARMA
Shrinking 60% of lung cancers, Blueprint`s RET drug poised for 2020 filing
04 Jun 2019 //
FIERCE BIOTECH
15 new cancer drugs debuted in 2018—along with one big leap in drug spending
31 May 2019 //
FIERCE PHARMA
Bayer to work with Foundation Medicine on selecting cancer patients
29 May 2019 //
REUTERS
Bayer posts early clinical data on follow-up to Loxo’s Vitrakvi
01 Apr 2019 //
FIERCE BIOTECH
As Lilly deal closes, Bayer secures full rights to Loxo`s Vitrakvi
16 Feb 2019 //
BIOPHARMA DIVE
Lilly Completes Acquisition of Loxo Oncology
15 Feb 2019 //
BIOSPACE
Bayer obtains full rights to Vitrakvi® (larotrectinib)& BAY 2731954 (LOXO-195)
15 Feb 2019 //
PR NEWSWIRE
Pharma companies clear the R&D decks in Q4
11 Feb 2019 //
PHARMAPHORUM
Lilly cuts a trio of pipeline assets, including BTK inhibitor, diabetes drug
07 Feb 2019 //
FIERCE BIOTECH
Eli Lilly backs U.S. proposal on drug rebates to lower costs
07 Feb 2019 //
REUTERS
Pharma Catches Another Case Of M&A Fever
01 Feb 2019 //
MARKET WATCH
A flashy 2019 start to pharma M&A, but will it last?
28 Jan 2019 //
BIOPHARMA DIVE
JPM 2019: Lilly buys Loxo, Pfizer’s biosimilar bundle and $22 coffee
22 Jan 2019 //
BIOPROCESS INTL
5 Potential Biotech M&A Targets To Watch In 2019
22 Jan 2019 //
SEEKING ALPHA
No bidding war for Loxo, so did Lilly overpay?
19 Jan 2019 //
FIERCE PHARMA
Eli Lilly rushed to put its $8B buyout deal together for Loxo in 10 days
18 Jan 2019 //
ENDPTS
A Planned Spinoff Of Cancer Vaccines At Generex
14 Jan 2019 //
SEEKING ALPHA
Lilly eyes more cancer deals, but wary of CAR-T, gene therapy
12 Jan 2019 //
REUTERS
M&A, IPOs and VC raises: Biotech, medtech execs look to 2019
12 Jan 2019 //
FIERCE BIOTECH
